SAN DIEGO, May 21, 2018 /PRNewswire/ -- Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced its presentation opportunities at several key scientific and industry meetings.
2018 BIO International Convention – Panel Participation
The 2018 BIO International Convention is being held June 4-7th in Boston, MA.
2018 American Society for Microbiology (ASM) Meeting – 3 Poster Presentations
The 2018 ASM Microbe meeting is being held June 7-11th in Atlanta, GA. Abstracts can be found by accessing the ASM meeting planner below:
http://www.abstractsonline.com/pp8/#!/4623/session/1500
http://www.abstractsonline.com/pp8/#!/4623/session/1368
Session 048: AAR Late-Breakers
Session 415: AAR08 – New Antimicrobial Agents and New Research Technologies
2018 Gordon Research Conference (GRC) Metals in Medicine Meeting – Oral Presentation
The 2018 GRC Metals in Medicine meeting is being held June 24th-29th in Andover, NH. Conference Chairs include Prof. Seth Cohen, Ph.D., Forge's scientific co-founder and a member of its Scientific Advisory Board, professor and former Chair of the Department of Chemistry and Biochemistry at the University of California, San Diego (UCSD).
BLACKSMITH Platform & Strategy
Forge's platform called BLACKSMITH comprises a deep knowledge of metalloenzymes, bioinorganic and medicinal chemistry know-how, and a focused fragment library of proprietary metal-binding pharmacophores (MBPs) that provide selective & diverse starting points for novel inhibitors. Our strategy is to use the BLACKSMITH platform to discover new chemical matter to address unmet needs for the treatment of a broad range of diseases, with initial efforts in the area of infectious disease.
About Forge Therapeutics
At Forge Therapeutics, we are developing medicines targeting metal-dependent enzymes found in nature. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese, calcium, cobalt, and copper are the essential ingredient in these metalloenzymes. At Forge, we are the BLACKSMITHS of modern medicine, providing the tools to address any metalloenzyme challenge.
Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria, which is essential for bacteria to grow. Forge has a strategic drug discovery alliance with Evotec AG and has been awarded multiple government awards including CARB-X. In addition, Forge has amassed a rich intellectual property estate on metalloenzyme-targeted inhibitors to protect its BLACKSMITH platform and pipeline including technology licensed from UCSD. For further information, please visit the company's website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.
Forge Company Contact:
Info@ForgeTherapeutics.com
Forge Media Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243
SOURCE Forge Therapeutics, Inc.